TinyGemsBreaks Archive - Page 115 of 124

MondayJul 18, 2022 12:50 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Partners to Propel New, Exciting Growth Opportunities

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently entered into agreements with beverage developer BevNology. “The BevNology collaboration not only includes a commercial license agreement for products with active ingredients derived from hemp under BevNology’s brand but also a manufacturing operating agreement utilizing BevNology’s new, custom-built state-of-the-art processing facility outside Atlanta…. The manufacturing agreement will help Lexaria broaden its production capabilities for its own growing list of B2B clientele interested in purchasing DehydraTECH-powered active ingredients for consumer-packaged-goods brands. Lexaria has already installed all required commercial DehydraTECH manufacturing equipment at the facility,” a recent article reads.…

MondayJul 18, 2022 10:41 am

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Appoints Michael Woudenberg as Chief Operating Officer

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced its appointment of Michael Woudenberg as chief operating officer of the company, overseeing all day-to-day operations. Woudenberg previously served as senior vice president of chemistry, manufacturing and controls. For the past several years, he has been an integral part of InMed’s executive team, supporting multiple functions within the organization. Prior to joining InMed, Woudenberg had over 20 years of successful drug development, process engineering, GMP manufacturing and general management experience at all levels of various companies. “I would like to congratulate Mike…

FridayJul 15, 2022 1:14 pm

TinyGemsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Maintains String of Profitability in 15 Consecutive Quarters

Golden Matrix (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, continues to grow every quarter, returning value to shareholders. “While many companies languished through the COVID-19 pandemic, GMGI maintained its string of profitability, which has now been extended to 15 straight quarters. From beginning of this fiscal year, the company began realizing the benefits of the RKings acquisition, which further bolstered the top and bottom lines. Revenue for the quarter ended April 30, 2022, was $8.48 million, up 221% from $2.64 million in the year prior quarter. Net income was $586,984, a gain of…

FridayJul 15, 2022 12:37 pm

TinyGemsBreaks – Cepton Inc. (NASDAQ: CPTN) Working to Make Lidar a Standard Feature of Today’s Cars, Key Component of Future Autonomous Vehicles

Cepton (NASDAQ: CPTN) is an innovator and leader specializing in high-performance Micro Motion Technology (“MMT(R)”) lidar solutions that enable reliable, scalable, long-range, high-resolution 3D perception for smart applications. The company was recently added to the Russell 3000(R) Index, effective June 27, 2022, following its rapid growth over the last year. According to co-founder and CEO Dr. Jun Pei, the inclusion in the Russell 3000(R) Index enables the company to “expand awareness of our story among the investment community as we continue to execute against our milestones generating long-term stakeholder value.” Meanwhile, the company plans to utilize its new corporate office…

ThursdayJul 14, 2022 1:59 pm

TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Equipping Physicians, Individuals with Comprehensive Immune System Views

Aditxt (NASDAQ: ADTX) provides the AditxtScore(TM), a proprietary immune mapping technology designed to provide a personalized profile of the immune system. “Licensed from Stanford University, AditxtScore(TM) for COVID-19 is Aditxt’s first commercial product. It enables patients to know the level of protection that an immune response to the SARS-CoV-2 virus or vaccination confers them…The results may also influence the vaccine-hesitant populace to take the vaccine, particularly when it is determined that they are not protected by antibodies. Generally, the AditxtScore(TM) results offer information on whether an individual has antibodies that will protect them against the virus; if the antibodies are…

ThursdayJul 14, 2022 1:05 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Awarded Patent in Japan, Submits Briefing Book

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, announced that it has been notified that it will be awarded a new patent in Japan, which makes the 26th world patent for the company. The patent, which is the third one granted in Japan, recognizes the company’s patented drug-delivery technology, DehydraTECH(TM), and its ability to deliver active pharmaceutical ingredients (“APIs”) more efficiently, regardless of the “food effect,” or the presence of food in the gastrointestinal system. Drug delivery is a key component of reliable drug dosing. According to the announcement, this is the first patent issued from Lexaria’s seventh…

WednesdayJul 13, 2022 4:08 pm

TinyGemsBreaks – QSAM Biosciences Inc. (QSAM) Expands IP Estate with Receipt of Third US Patent for CycloSam(R)

QSAM Biosciences (OTCQB: QSAM) is a company developing next-generation targeted therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (“CycloSam(R)”), for the treatment of cancer and related diseases. The company today announced that the United States Patent & Trademark Office has granted a key patent protecting how CycloSam(R) is formulated and prepared, namely by using a nonradioactive kit that can be delivered and stored local to the administration site and provides for high purity in an efficient, facile and reproducible process at lower costs. “This patent issuance marks our third granted patent in the United States and further strengthens our IP estate, consisting of 14…

WednesdayJul 13, 2022 2:38 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Nearing Start Date for Its Human Nicotine Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the pending start of its upcoming human nicotine study NIC-H22-1. Through the study, Lexaria expects to evidence that processing purified nicotine with its patented drug delivery technology, DehydraTECH(TM), leads to enhanced oral-tissue absorption and reduced negative experiences. NIC-H22-1, a minimum 36-person human pharmacokinetic (“PK”) randomized, double blinded, cross-over study, will compare Lexaria’s DehydraTECH-nicotine pouch performance to that of existing leading brands currently sold in the U.S. such as ON! and Zyn. The primary objective of the study is data collection from blood samples that will evidence…

WednesdayJul 13, 2022 2:21 pm

TinyGemsBreaks – Standard Lithium Ltd (TSX.V: SLI) (NYSE American: SLI) (FRA: S5L) Releases Update on Key Developments

Standard Lithium (TSX.V: SLI) (NYSE American: SLI) (FRA: S5L), an innovative technology and lithium project-development company, is reporting on recent corporate and project developments. Highlights of the update include additions to SLI management, a master service agreement (“MSA”) with Telescope Innovations (“TELI”), the progress of a DFS/FEED study award and increased shareholdings by senior management. Specifically, SLI named new positions and members to its management team, including Jason Tielker as vice president of project delivery and Angus Remfry as director of project delivery. In addition, the company is reviewing Pre-FEED deliverables related to its first commercial plant with the anticipation…

TuesdayJul 12, 2022 3:22 pm

TinyGemsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB003 Phase 1/2a Clinical Trial Through Clinilabs Begins Enrollment

Clinilabs Drug Development Corporation, a global, full-service contract research organization with deep expertise in central nervous system drug development, today announced commencement of enrollment in a phase 1/2a clinical trial of CYB003. Being developed by Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” CYB003 is the first novel psilocybin analog to be evaluated in phase 1/2a development for the treatment of major depressive disorder (“MDD”). “Clinilabs is honored to be working with Cybin, an innovator in the development of novel psychedelic therapeutics, to conduct its first-in-human clinical trial of CYB003,” said…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

TinyGemsBreaks